{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:24:35Z","timestamp":1789010675578,"version":"build-2803163510"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>To date, there is no treatment with proven efficacy for cutaneous leukocytoclastic vasculitis (CLV). Several reports have suggested that CLV responds favorably to corticosteroids, colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs), azathioprine, and hydroxychloroquine (HCQ). To the best of our knowledge, the oral small molecule Janus kinase inhibitor, tofacitinib, plays an important role in the treatment of autoimmune and inflammatory diseases. Therefore, tofacitinib may be a prospective therapy in patients with CLV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Presentation<\/jats:title><jats:p>A 29-year-old woman presented to our hospital with a 5-year history of symmetric skin lesions mainly affecting both lower extremities. The results for anti-neutrophil cytoplasmic antibodies (ANCA), anti-extracted nuclear antigens (ENA) autoantibodies, anti-double-stranded deoxyribonucleic acid (dsDNA)\u00a0antibodies, and antinuclear antibodies (ANA) were all negative. The definite diagnosis of CLV was determined by a skin biopsy. However, the patient exhibited a poor response to prednisone, HCQ, methotrexate, colchicine, azathioprine, and tripterygium wilfordii polyglycoside tablets (TGTs) treatments. She was then treated with oral tofacitinib (5 mg twice daily) and oral prednisone (25 mg daily).<\/jats:p><\/jats:sec><jats:sec><jats:title>Outcomes<\/jats:title><jats:p>Her skin lesions gradually improved over a period of 4 weeks. Two months later, the skin ulcers completely resolved. No evidence of recurrence of skin ulcers was observed during a 6-month follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We present the first case of a female patient receiving short-term tofacitinib therapy for refractory CLV. Tofacitinib may be a promising oral alternative for patients with CLV. However, its efficacy and safety require further appraisal through clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2021.695768","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T06:37:43Z","timestamp":1624516663000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Tofacitinib Treatment of Refractory Cutaneous Leukocytoclastic Vasculitis: A Case Report"],"prefix":"10.3389","volume":"12","author":[{"given":"Kai-Jun","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Dan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199711203372106","article-title":"Small-Vessel Vasculitis","volume":"337","author":"Jennette","year":"1997","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/tbj.13218","article-title":"Tamoxifen Induced Non-Purpuric Cutaneous Leukocytoclastic Vasculitis","volume":"25","author":"Joseph","year":"2019","journal-title":"Breast J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-0488.18.05886-8","article-title":"Cutaneous and Systemic Vasculitides in Dermatology: A Histological Perspective","volume":"153","author":"Alberti-Violetti","year":"2018","journal-title":"G Ital Dermatol Venereol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12275678","article-title":"Human Hypersensitivity Angiitis, an Immune Complex Disease","volume":"85","author":"Sams","year":"1985","journal-title":"J Invest Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1001\/archderm.118.5.296","article-title":"Leukocytoclastic Vasculitis","volume":"118","author":"Mackel","year":"1982","journal-title":"Arch Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2014.04.015","article-title":"Incidence of Leukocytoclastic Vasculitis, 1996 to 2010: A Population-Based Study in Olmsted County, Minnesota","volume":"89","author":"Arora","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.120.4.484","article-title":"Cutaneous Leukocytoclastic Vasculitis. Clinical and Laboratory Features of 82 Patients Seen in Private Practice","volume":"120","author":"Ekenstam","year":"1984","journal-title":"Arch Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.03.024","article-title":"Early Prednisone Therapy in Henoch-Sch\u00f6nlein Purpura: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"149","author":"Ronkainen","year":"2006","journal-title":"J Pediatr"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(84)90518-9","article-title":"The Hypocomplementemic Urticarial-Vasculitis Syndrome: Therapeutic Response to Hydroxychloroquine","volume":"73","author":"Lopez","year":"1984","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/030097401317148499","article-title":"Leucocytoclastic Vasculitis: An Update for the Clinician","volume":"30","author":"Koutkia","year":"2001","journal-title":"Scand J Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030423","article-title":"Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis","volume":"137","author":"Zhang","year":"2018","journal-title":"Circulation."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1512404","article-title":"Tofacitinib for the Treatment of Psoriasis and Psoriatic Arthritis","volume":"14","author":"Berekmeri","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.08.005","article-title":"Skin Involvement in Cutaneous and Systemic Vasculitis","volume":"12","author":"Marzano","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/09546630500277971","article-title":"Management of Leukocytoclastic Vasculitis","volume":"16","author":"Sunderk\u00f6tter","year":"2005","journal-title":"J Dermatolog Treat"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.212","article-title":"Cutaneous Vasculitis","volume":"48","author":"Fiorentino","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.131.12.1399","article-title":"Colchicine in the Treatment of Cutaneous Leukocytoclastic Vasculitis. Results of a Prospective, Randomized Controlled Trial","volume":"131","author":"Sais","year":"1995","journal-title":"Arch Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s0738-081x(99)00074-7","article-title":"A Clinical Approach to the Vasculitis Patient in the Dermatologic Office","volume":"17","author":"Callen","year":"1999","journal-title":"Clin Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/003591576906200712","article-title":"Allergic Vasculitis(Tri-Symptom of Gougerot) Treated With Dapsone","volume":"62","author":"Wells","year":"1969","journal-title":"Proc R Soc Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.2.167","article-title":"Low-Dose Methotrexate Controls a Severe Form of Polyarteritis Nodosa","volume":"136","author":"Boehm","year":"2000","journal-title":"Arch Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/pde.13911","article-title":"Pediatric Red Ear Syndrome: A Case Report of an Erythromelalgia Type and Review of the Literature","volume":"36","author":"Cinats","year":"2019","journal-title":"Pediatr Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e20182845","DOI":"10.1542\/peds.2018-2845","article-title":"Tofacitinib Treatment of Refractory Systemic Juvenile Idiopathic Arthritis","volume":"143","author":"Huang","year":"2019","journal-title":"Pediatrics"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1707500","article-title":"Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"377","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.695768\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T06:37:45Z","timestamp":1624516665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.695768\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,24]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2021.695768"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.695768","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,24]]},"article-number":"695768"}}